Participate in a Study 

register_now_copy

Current Studies

Type 1 Diabetes Trials:

Study – LPS14947

  • Participant must be 18 to 70 years of age.
  • Participants with T1DM.
  • Participants treated with multiple daily injections (MDI) using basal insulin analog once daily and rapid acting insulin analogs for at least one year.
  • HbA1c ≥7% (48 mmol/mol) and ≤ 10% (86 mmol/mol) at screening.

Type 2 Diabetes Trials:

Study – EX4473

  • Male or female, age ≥50 years at the time of signing informed consent
  • Diagnosed with type 2 diabetes mellitus
  • HbA1c 6.5% - 10.0% (47 - 86 mmol/mol) (both inclusive)a
  • At least one of the below conditions (a-d):
    • Coronary heart disease
    • Cerebrovascular disease
    • Symptomatic peripheral artery disease (PAD)
    • Chronic kidney disease defined as:
  • eGFR < 60 mL/min/1.73 m2 b

Study – NN4321

  • Male or female, age ≥ 18 years at the time of signing informed consent.
  • Diagnosed with type 2 diabetes mellitus
  • HbA1c ≤ 10% (≤ 86 mmol/mol)
  • Renal impairment defined either by:
    • serum creatinine-based eGFR ≥ 50 and ≤ 75 mL/min/1.73 m2 (CKD-EPI) and UACR > 300 and < 5000 mg/g
      or
    • serum creatinine-based eGFR ≥ 25 and 100 and < 5000 mg/g

Study – NN4352

  • Male or female, age ≥18 years at the time of signing informed consent.
  • Diagnosed with type 2 diabetes mellitus ≥ 10 years prior to the day of screening.
  • HbA1c of 7.0-10.0% (53-86 mmol/mol) (both inclusive).

Study - EFC14875

  • 1 year / 15 office visits / 16 phone visits
  • Type 2 diabetes with HbA1c ≥7% (53 mmol/mol) at Screening
  • Patients either:
    • Age ≥18 years with at least 1 (one) of the major CV risk factor
    • OR
    • In the absence of a major CV risk factor, age ≥55 years with at least 2 (two)of minor CV risk factors

Type 1 or 2 Diabetes Trials:

Study – CIP318

  • Subject is 2-75 years of age at time of screening
  • A clinical diagnosis of type 1 or type 2 diabetes as determined by investigator, for at least the last 12 months
  • Subject is using insulin to treat their diabetes
  • Subject agrees to comply with the study protocol requirements
  • Subject is willing to perform SMBG approximately every 15 minutes (Phase 1)/20 minutes (Phase 2) during FST
 
Endocrine Research Solutions, Inc.
1475 Holcomb Bridge Road, Suite 129, Roswell, GA 30076
Ph: 678.878.4750 Fx: 678.878.4751